Target Binding Site Detail
| Target General Information | Top | ||||
|---|---|---|---|---|---|
| Target ID | T23172 | Target Info | |||
| Target Name | Janus kinase 3 (JAK-3) | ||||
| Synonyms | Tyrosine-protein kinase JAK3; Leukocyte janus kinase; L-JAK | ||||
| Target Type | Successful Target | ||||
| Gene Name | JAK3 | ||||
| Biochemical Class | Kinase | ||||
| UniProt ID | |||||
| Ligand General Information | Top | ||||
|---|---|---|---|---|---|
| Ligand Name | Phosphonotyrosine | Ligand Info | |||
| Canonical SMILES | C1=CC(=CC=C1CC(C(=O)O)N)OP(=O)(O)O | ||||
| InChI | 1S/C9H12NO6P/c10-8(9(11)12)5-6-1-3-7(4-2-6)16-17(13,14)15/h1-4,8H,5,10H2,(H,11,12)(H2,13,14,15)/t8-/m0/s1 | ||||
| InChIKey | DCWXELXMIBXGTH-QMMMGPOBSA-N | ||||
| PubChem Compound ID | 30819 | ||||
| Drug Binding Sites of Target | Top | |||||
|---|---|---|---|---|---|---|
| PDB ID: 4Z16 Crystal Structure of the Jak3 Kinase Domain Covalently Bound to N-(3-(((5-chloro-2-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)methyl)phenyl)acrylamide | ||||||
| Method | X-ray diffraction | Resolution | 2.90 Å | Mutation | No | [1] |
| PDB Sequence |
PTIFEERHLK
823 YISQLGKGNF833 GSVELCRYDP843 LGDNTGALVA853 VKQLQHSGPD863 QQRDFQREIQ 873 ILKALHSDFI883 VKYRGVSYEL898 RLVMEYLPSG908 CLRDFLQRHR918 ARLDASRLLL 928 YSSQICKGME938 YLGSRRCVHR948 DLAARNILVE958 SEAHVKIADF968 GLAKLLPLDK 978 DVVRPIFWYA995 PESLSDNIFS1005 RQSDVWSFGV1015 VLYELFTYCD1025 KSCSPSAEFL 1035 RMMALCRLLE1052 LLEEGQRLPA1062 PPACPAEVHE1072 LMKLCWAPSP1082 QDRPSFSALG 1092 PQLDMLWSGS1102 R
|
|||||
|
|
||||||
| PDB ID: 7C3N Crystal structure of JAK3 in complex with Delgocitinib | ||||||
| Method | X-ray diffraction | Resolution | 1.98 Å | Mutation | No | [2] |
| PDB Sequence |
PTIFEERHLK
823 YISQLGKGNF833 GSVELCRYDP843 LGDNTGALVA853 VKQLQHSGPD863 QQRDFQREIQ 873 ILKALHSDFI883 VKYRGVSYGP893 GRQSLRLVME903 YLPSGCLRDF913 LQRHRARLDA 923 SRLLLYSSQI933 CKGMEYLGSR943 RCVHRDLAAR953 NILVESEAHV963 KIADFGLAKL 973 LPLDKDVVRE985 PGQSPIFWYA995 PESLSDNIFS1005 RQSDVWSFGV1015 VLYELFTYCD 1025 KSCSPSAEFL1035 RMMGCERDVP1045 ALCRLLELLE1055 EGQRLPAPPA1065 CPAEVHELMK 1075 LCWAPSPQDR1085 PSFSALGPQL1095 DMLWSGS
|
|||||
|
|
||||||
| PDB ID: 7UYV Crystal structure of JAK3 kinase domain in complex with compound 25 | ||||||
| Method | X-ray diffraction | Resolution | 2.15 Å | Mutation | No | [3] |
| PDB Sequence |
PTIFEERHLK
823 YISQLGKGNF833 GSVELCRYDP843 LGDNTGALVA853 VKQLQHSGPD863 QQRDFQREIQ 873 ILKALHSDFI883 VKYRGVSYQS897 LRLVMEYLPS907 GCLRDFLQRH917 RARLDASRLL 927 LYSSQICKGM937 EYLGSRRCVH947 RDLAARNILV957 ESEAHVKIAD967 FGLAKLLPLD 977 KDVVREPGQS989 PIFWYAPESL999 SDNIFSRQSD1009 VWSFGVVLYE1019 LFTYCDKSCS 1029 PSAEFLRMMV1044 PALSRLLELL1054 EEGQRLPAPP1064 ACPAEVHELM1074 KLCWAPSPQD 1084 RPSFSALGPQ1094 LDMLWS
|
|||||
|
|
||||||
| PDB ID: 1YVJ Crystal structure of the Jak3 kinase domain in complex with a staurosporine analogue | ||||||
| Method | X-ray diffraction | Resolution | 2.55 Å | Mutation | Yes | [4] |
| PDB Sequence |
PTIFEERHLK
823 YISQLGKGNF833 GSVELCRYDP843 LGDNTGALVA853 VKQLQHSGPD863 QQRDFQREIQ 873 ILKALHSDFI883 VKYRGVSYGP893 GRPELRLVME903 YLPSGCLRDF913 LQRHRARLDA 923 SRLLLYSSQI933 CKGMEYLGSR943 RCVHRDLAAR953 NILVESEAHV963 KIADFGLAKL 973 LPLDKDVVRE985 PGQSPIFWYA995 PESLSDNIFS1005 RQSDVWSFGV1015 VLYELFTYCD 1025 KSCSPSAEFL1035 RMMGCERDVP1045 ALCRLLELLE1055 EGQRLPAPPA1065 CPAEVHELMK 1075 LCWAPSPQDR1085 PSFSALGPQL1095 DMLWSGSR
|
|||||
|
Click to Show 3D Structure of This Binding Site
set background white;style ions nothing; color 8e8e8e;style chemicals nothing; select .PTR or .PTR2 or .PTR3 or :3PTR;style chemicals stick;color identity;select .A:972 or .A:973 or .A:974 or .A:975 or .A:978 or .A:979 or .A:982 or .A:983 or .A:1002 or .A:1003 or .A:1004 or .A:1005; color #f3c393; zoom selection;set surface opacity 0.5;set surface Van der Waals surface;set mode all
|
||||||
| PDB ID: 3ZEP Crystal Structure of JAK3 Kinase Domain in Complex with a Pyrrolopyrazine-2-phenyl Ether Inhibitor | ||||||
| Method | X-ray diffraction | Resolution | 2.35 Å | Mutation | Yes | [5] |
| PDB Sequence |
PTIFEERHLK
823 YISQLGKGNF833 GSVELCRYDP843 LGDNTGALVA853 VKQLQHSGPD863 QQRDFQREIQ 873 ILKALHSDFI883 VKYRGVSYSL898 RLVMEYLPSG908 CLRDFLQRHR918 ARLDASRLLL 928 YSSQICKGME938 YLGSRRCVHR948 DLAARNILVE958 SEAHVKIADF968 GLAKLLPLDK 978 DVVREPGQSP990 IFWYAPESLS1000 DNIFSRQSDV1010 WSFGVVLYEL1020 FTYCDKSCSP 1030 SAEFLRMMGS1040 PALSRLLELL1054 EEGQRLPAPP1064 ACPAEVHELM1074 KLCWAPSPQD 1084 RPSFSALGPQ1094 LDML
|
|||||
|
Click to Show 3D Structure of This Binding Site
set background white;style ions nothing; color 8e8e8e;style chemicals nothing; select .PTR or .PTR2 or .PTR3 or :3PTR;style chemicals stick;color identity;select .A:972 or .A:973 or .A:974 or .A:975 or .A:978 or .A:979 or .A:982 or .A:983 or .A:1002 or .A:1003 or .A:1004 or .A:1005; color #00ffc7; zoom selection;set surface opacity 0.5;set surface Van der Waals surface;set mode all
|
||||||
| PDB ID: 3ZC6 Crystal structure of JAK3 kinase domain in complex with an indazole substituted pyrrolopyrazine inhibitor | ||||||
| Method | X-ray diffraction | Resolution | 2.42 Å | Mutation | Yes | [6] |
| PDB Sequence |
PTIFEERHLK
823 YISQLGKGNF833 GSVELCRYDP843 LGDNTGALVA853 VKQLQHSGPD863 QQRDFQREIQ 873 ILKALHSDFI883 VKYRGVSYGS897 LRLVMEYLPS907 GCLRDFLQRH917 RARLDASRLL 927 LYSSQICKGM937 EYLGSRRCVH947 RDLAARNILV957 ESEAHVKIAD967 FGLAKLLPLD 977 KDVVQSPIFW993 YAPESLSDNI1003 FSRQSDVWSF1013 GVVLYELFTY1023 CDKSCSPSAE 1033 FLRMMGSERD1043 VPALSRLLEL1053 LEEGQRLPAP1063 PACPAEVHEL1073 MKLCWAPSPQ 1083 DRPSFSALGP1093 QLDMLWS
|
|||||
|
Click to Show 3D Structure of This Binding Site
set background white;style ions nothing; color 8e8e8e;style chemicals nothing; select .PTR or .PTR2 or .PTR3 or :3PTR;style chemicals stick;color identity;select .A:972 or .A:973 or .A:974 or .A:975 or .A:978 or .A:979 or .A:982 or .A:983 or .A:1002 or .A:1003 or .A:1004 or .A:1005; color #f3c393; zoom selection;set surface opacity 0.5;set surface Van der Waals surface;set mode all
|
||||||
| PDB ID: 5W86 CRYSTAL STRUCTURE OF JAK3 KINASE DOMAIN WITH A 4,6-DIAMINONICOTINAMIDE INHIBITOR (COMPOUND NUMBER 7) | ||||||
| Method | X-ray diffraction | Resolution | 2.61 Å | Mutation | Yes | [7] |
| PDB Sequence |
PTIFEERHLK
823 YISQLGKGSV836 ELCRYDPLGD846 NTGALVAVKQ856 LQHSGPDQQR866 DFQREIQILK 876 ALHSDFIVKY886 RGVSYLRLVM902 EYLPSGCLRD912 FLQRHRARLD922 ASRLLLYSSQ 932 ICKGMEYLGS942 RRCVHRDLAA952 RNILVESEAH962 VKIADFGLAK972 LLPLDKDVVS 989 PIFWYAPESL999 SDNIFSRQSD1009 VWSFGVVLYE1019 LFTYCDKSCS1029 PSAEFLRMMG 1039 SERDVPALSR1049 LLELLEEGQR1059 LPAPPACPAE1069 VHELMKLCWA1079 PSPQDRPSFS 1089 ALGPQLDML
|
|||||
|
Click to Show 3D Structure of This Binding Site
set background white;style ions nothing; color 8e8e8e;style chemicals nothing; select .PTR or .PTR2 or .PTR3 or :3PTR;style chemicals stick;color identity;select .A:972 or .A:973 or .A:974 or .A:975 or .A:978 or .A:979 or .A:982 or .A:983 or .A:1002 or .A:1003 or .A:1004 or .A:1005; color #00ffc7; zoom selection;set surface opacity 0.5;set surface Van der Waals surface;set mode all
|
||||||
| PDB ID: 6AAK Crystal structure of JAK3 in complex with peficitinib | ||||||
| Method | X-ray diffraction | Resolution | 2.67 Å | Mutation | Yes | [8] |
| PDB Sequence |
TIFEERHLKY
824 ISQLGKGNFG834 SVELCRYDPL844 GDNTGALVAV854 KQLQHSGPDQ864 QRDFQREIQI 874 LKALHSDFIV884 KYRGVSYQSL898 RLVMEYLPSG908 CLRDFLQRHR918 ARLDASRLLL 928 YSSQICKGME938 YLGSRRCVHR948 DLAARNILVE958 SEAHVKIADF968 GLAKLLPLDK 978 DVVREPGQSP990 IFWYAPESLS1000 DNIFSRQSDV1010 WSFGVVLYEL1020 FTYCDKSCSP 1030 SAEFLRMMRD1043 VPALSRLLEL1053 LEEGQRLPAP1063 PACPAEVHEL1073 MKLCWAPSPQ 1083 DRPSFSALGP1093 QLDML
|
|||||
|
Click to Show 3D Structure of This Binding Site
set background white;style ions nothing; color 8e8e8e;style chemicals nothing; select .PTR or .PTR2 or .PTR3 or :3PTR;style chemicals stick;color identity;select .A:870 or .A:972 or .A:973 or .A:974 or .A:975 or .A:978 or .A:979 or .A:982 or .A:983 or .A:1002 or .A:1003 or .A:1004 or .A:1005; color #f3c393; zoom selection;set surface opacity 0.5;set surface Van der Waals surface;set mode all
|
||||||
| PDB ID: 6HZV HUMAN JAK3 IN COMPLEX WITH LASW959 PROTEIN IN COMPLEX WITH LIGAND | ||||||
| Method | X-ray diffraction | Resolution | 2.46 Å | Mutation | No | [9] |
| PDB Sequence |
TIFEERHLKY
824 ISQLGKGNFG834 SVELCRYDPL844 GDNTGALVAV854 KQLQGPDQQR866 DFQREIQILK 876 ALHSDFIVKY886 RGVSYQSLRL900 VMEYLPSGCL910 RDFLQRHRAR920 LDASRLLLYS 930 SQICKGMEYL940 GSRRCVHRDL950 AARNILVESE960 AHVKIADFGL970 AKLLPLDKDV 982 VRPIFWYAPE997 SLSDNIFSRQ1007 SDVWSFGVVL1017 YELFTYCDKS1027 CSPSAEFLRM 1037 PALSRLLELL1054 EEGQRLPAPP1064 ACPAEVHELM1074 KLCWAPSPQD1084 RPSFSALGPQ 1094 LDML
|
|||||
|
Click to Show 3D Structure of This Binding Site
set background white;style ions nothing; color 8e8e8e;style chemicals nothing; select .PTR or .PTR2 or .PTR3 or :3PTR;style chemicals stick;color identity;select .A:870 or .A:972 or .A:974 or .A:975 or .A:978 or .A:979 or .A:982 or .A:983 or .A:1002 or .A:1003 or .A:1004 or .A:1005; color #00ffc7; zoom selection;set surface opacity 0.5;set surface Van der Waals surface;set mode all
|
||||||
| PDB ID: 4V0G JAK3 in complex with a covalent EGFR inhibitor | ||||||
| Method | X-ray diffraction | Resolution | 3.00 Å | Mutation | No | [10] |
| PDB Sequence |
> Chain A
FEERHLKYIS 826 QLGKGNFGSV836 ELCRYDPLGD846 NTGALVAVKQ856 LQHSGPDQQR866 DFQREIQILK 876 ALHSDFIVKY886 RGVSYGSLRL900 VMEYLPSGCL910 RDFLQRHRAR920 LDASRLLLYS 930 SQICKGMEYL940 GSRRCVHRDL950 AARNILVESE960 AHVKIADFGL970 AKLLPLDKDV 982 VREPIFWYAP996 ESLSDNIFSR1006 QSDVWSFGVV1016 LYELFTYCDK1026 SCSPSAEFLR 1036 MMVPALSRLL1051 ELLEEGQRLP1061 APPACPAEVH1071 ELMKLCWAPS1081 PQDRPSFSAL 1091 GPQLDML> Chain B IFEERHLKYI 825 SQLGKGNFGS835 VELCRYDPLG845 DNTGALVAVK855 QLQHSGPDQQ865 RDFQREIQIL 875 KALHSDFIVK885 YRGVSYGSLR899 LVMEYLPSGC909 LRDFLQRHRA919 RLDASRLLLY 929 SSQICKGMEY939 LGSRRCVHRD949 LAARNILVES959 EAHVKIADFG969 LAKLLPLDKD 979 VVRPIFWYAP996 ESLSDNIFSR1006 QSDVWSFGVV1016 LYELFTYCDK1026 SCSPSAEFLR 1036 MMGSERDVPA1046 LSRLLELLEE1056 GQRLPAPPAC1066 PAEVHELMKL1076 CWAPSPQDRP 1086 SFSALGPQLD1096 ML
|
|||||
|
Click to Show 3D Structure of This Binding Site
set background white;style ions nothing; color 8e8e8e;style chemicals nothing; select .PTR or .PTR2 or .PTR3 or :3PTR;style chemicals stick;color identity;select .A:870 or .A:972 or .A:973 or .A:974 or .A:975 or .A:978 or .A:979 or .A:982 or .A:983 or .A:1002 or .A:1003 or .A:1004 or .A:1005 or .B:935 or .B:938 or .B:870 or .B:972 or .B:973 or .B:974 or .B:975 or .B:978 or .B:979 or .B:982 or .B:983 or .B:1002 or .B:1003 or .B:1004 or .B:1005; color #f3c393; zoom selection;set surface opacity 0.5;set surface Van der Waals surface;set mode all
|
ARG870[A]
3.270
LYS972[A]
3.327
LEU973[A]
3.374
LEU974[A]
3.884
PRO975[A]
3.683
LYS978[A]
3.026
ASP979[A]
1.332
VAL982[A]
1.333
VAL983[A]
3.533
ASN1002[A]
3.814
ILE1003[A]
3.561
PHE1004[A]
2.680
SER1005[A]
4.386
LYS935[B]
3.532
|
|||||
| References | Top | ||||
|---|---|---|---|---|---|
| REF 1 | Development of Selective Covalent Janus Kinase 3 Inhibitors. J Med Chem. 2015 Aug 27;58(16):6589-606. | ||||
| REF 2 | Discovery of a Janus Kinase Inhibitor Bearing a Highly Three-Dimensional Spiro Scaffold: JTE-052 (Delgocitinib) as a New Dermatological Agent to Treat Inflammatory Skin Disorders. J Med Chem. 2020 Jul 9;63(13):7163-7185. | ||||
| REF 3 | Potent and selective TYK2-JH1 inhibitors highly efficacious in rodent model of psoriasis. Bioorg Med Chem Lett. 2022 Oct 1;73:128891. | ||||
| REF 4 | Crystal structure of the Jak3 kinase domain in complex with a staurosporine analog. Blood. 2005 Aug 1;106(3):996-1002. | ||||
| REF 5 | Discovery of a series of novel 5H-pyrrolo[2,3-b]pyrazine-2-phenyl ethers, as potent JAK3 kinase inhibitors. Bioorg Med Chem Lett. 2013 May 1;23(9):2522-6. | ||||
| REF 6 | Strategic use of conformational bias and structure based design to identify potent JAK3 inhibitors with improved selectivity against the JAK family and the kinome. Bioorg Med Chem Lett. 2013 May 1;23(9):2793-800. | ||||
| REF 7 | Discovery and structure-based design of 4,6-diaminonicotinamides as potent and selective IRAK4 inhibitors. Bioorg Med Chem Lett. 2017 Nov 1;27(21):4908-4913. | ||||
| REF 8 | Discovery and structural characterization of peficitinib (ASP015K) as a novel and potent JAK inhibitor. Bioorg Med Chem. 2018 Oct 1;26(18):4971-4983. | ||||
| REF 9 | Identification of 2-Imidazopyridine and 2-Aminopyridone Purinones as Potent Pan-Janus Kinase (JAK) Inhibitors for the Inhaled Treatment of Respiratory Diseases. J Med Chem. 2019 Oct 24;62(20):9045-9060. | ||||
| REF 10 | Utilisation of Structure Based Design to Identify Novel, Irreversible Inhibitors of the Epidermal Growth Factor Receptor (Egfr) Harboring the Gatekeeper T790M Mutation | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.